Fasenra
Chemical Name | benralizumab |
Dosage Form | Injectable (subcutaneous; 30 mg/mL) |
Drug Class | Monoclonal antibodies |
System | Respiratory |
Company | AstraZeneca |
Approval Year | 2017 |
Indication
- Fasenra is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.